|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Characteristics | ALS Survival Group | ALS death group | P value | BOS group | IPS group | P value |
| Total number | 18 | 10 |  | 15 | 13 |  |
| Recipient-donor gender |  |  | **0.0490** |  |  | 1.000 |
| compatibilities | 13 | 3 |  | 9 | 7 |  |
| incompatibilities | 5 | 7 |  | 6 | 6 |  |
| Recipient-donor blood type |  |  | 1.000 |  |  | 0.255 |
| compatibilities | 10 | 5 |  | 10 | 5 |  |
| major incompatibilities | 6 | 4 |  | 4 | 6 |  |
| minor incompatibilities | 2 | 1 |  | 1 | 2 |  |
| Median age |  |  | 0.876 |  |  | 0.843 |
| Recipient | 11.5 (1~15) | 8.5 (1~16) |  | 12 (3~16) | 10 (1~15) |  |
| donor | 31 (8~68) | 34 (28~44) |  | 33 (8~68) | 34.5 (11~41) |  |
| Pre-transplant disease status |  |  | 1.000 |  |  | 1.000 |
| CR | 13 | 8 |  | 11 | 10 |  |
| PR or NR | 5 | 2 |  | 4 | 3 |  |
| Pulmonary infection before transplantation |  |  | 1.000 |  |  | 1.000 |
| Yes | 3 | 2 |  | 3 | 2 |  |
| No | 15 | 8 |  | 12 | 11 |  |
| TBI Conditioning |  |  | 0.847 |  |  | 0.529 |
| Yes | 4 | 3 |  | 9 | 9 |  |
| No | 14 | 7 |  | 6 | 4 |  |
| Transplantion type |  |  | 1.000 |  |  | 1.000 |
| Haplo-HSCT | 16 | 9 |  | 13 | 12 |  |
| MUD-HSCT | 2 | 1 |  | 2 | 1 |  |
| Graft reinfusion dose |  |  |  |  |  |  |
| MNC | 9.64 (5.45~18.35) | 10.64 (6.98~26.65) | 0.689 | 10.335 (5.45~18.35) | 9.195 (7.67~26.65) | 0.751 |
| CD34+ | 8.95 (1.88~15.59) | 7.345 (3.09~16.87) | 0.524 | 2.7 (1.88~15.59) | 5.695 (4.32~16.87) | 0.235 |
| CD3+ | 2.88 (0.26~4.63) | 2.46 (1.48~7.58) | 0.382 | 2.055 (1.03~4.63) | 1.585 (0.26~7.58) | 0.751 |
| Time to transplant |  |  |  |  |  |  |
| Diagnosis | 707.5 (79~2293) | 133 (90~2470) | 0.981 |  |  | 0.928 |
| Primary GVHD | +23.5 (8~204) | +25 (11~1218) | **0.021** |  |  | 0.786 |
| BOS/IPS | +188 (43~417) | +226.5 (30-1218) | 0.099 |  |  | 0.525 |
| ALS | +198 (47~665) | +361 (30~1218) | 0.099 |  |  | 0.316 |
| ALS appearance time |  |  | 0.207 |  |  | 0.198 |
| Early ALS（<100 days after HSCT） | 3 | 4 |  | 2 | 5 |  |
| Advanced ALS（>100 days after HSCT） | 15 | 6 |  | 13 | 8 |  |
| aGVHD |  |  | 0.731 |  |  | 0.098 |
| Ⅰ-Ⅱ | 12 | 7 |  | 9 | 10 |  |
| Ⅲ-Ⅳ | 6 | 3 |  | 6 | 3 |  |
| ALS combined with GVHD |  |  | 0.717 |  |  | 0.536 |
| aGVHD | 4 | 5 |  | 3 | 6 |  |
| cGVHD | 14 | 5 |  | 12 | 7 |  |
| ALS type |  |  | 0.674 |  |  | 0.670 |
| Single type | 6 | 6 |  | 5 | 7 |  |
| Mix type | 13 | 7 |  | 12 | 8 |  |
| Pre-ALS methylprednisolone dosage |  |  | **0.049** |  |  | 0.887 |
| ＜0.5mg/kg | 16 | 5 |  | 9 | 7 |  |
| ≥0.5mg/kg | 2 | 5 |  | 6 | 6 |  |
| Methylprednisolone dosage after ALS |  |  | 0.943 |  |  | 1.000 |
| Maintenance treatment | 6 | 4 |  | 6 | 4 |  |
| Increment≥1 time | 12 | 6 |  | 9 | 9 |  |
| Basic immunosuppressant |  |  | 0.088 |  |  | 0.221 |
| Cyclosporine | 7 | 2 |  | 6 | 6 |  |
| Tacrolimus | 11 | 8 |  | 9 | 7 |  |
| Second-line drugs |  |  |  |  |  |  |
| FAM | 14 | 2 | **0.005** | 11 | 5 | 0.125 |
| Imatinib | 8 | 2 | 0.247 | 8 | 2 | **0.055** |
| Ruxolitinib | 10 | 2 | 0.114 | 10 | 2 | **0.009** |
| Pirfenidone | 5 | 0 | 0.128 | 5 | 0 | **0.044** |
| Surgical operation | 2 | 2 | 0.601 | 2 | 2 | 1.000 |